Pacific Biosciences of California, Inc.PACBNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -32.79% | -4.27% | +10.42% | -3.82% | +13.82% |
| Gross Profit Growth | +5.09% | -112.15% | +147.29% | +50.62% | +66.52% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | -334.42% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | -1802.70% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | -1647.62% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | -1788.31% |
| Weighted Average Shares Growth | +6.85% | +10.12% | +10.20% | +10.23% | +6.68% |
| Weighted Average Shares Diluted Growth | +14.89% | +10.12% | +10.20% | +10.23% | -1.62% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -24.83% | +4.36% | -0.54% | +4.20% | +28.79% |
| Inventory Growth | +3.67% | -19.80% | -21.51% | -19.14% | -16.12% |
| Asset Growth | -27.81% | -48.45% | -45.31% | -44.61% | -37.79% |
| Book Value per Share Growth | -32.39% | -87.18% | -88.67% | -92.77% | -99.01% |
| Debt Growth | -28.00% | -24.94% | -24.40% | -23.64% | +12.94% |
| R&D Expense Growth | -38.34% | -33.14% | -41.46% | -10.46% | -16.70% |
| SG&A Expenses Growth | -10.54% | -5.28% | +1.28% | -28.91% | -17.25% |